Vanda Pharmaceuticals Inc. (VNDA) News
Follow Vanda Pharmaceuticals Inc. (VNDA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vanda Pharmaceuticals Reports Q3 Revenue Growth and Raises 2026 Guidance
Vanda reported third-quarter 2026 revenue of $69.8 million, up 24% year over year, and a net loss of $22.6 million, or $0.37 per share, unchanged from a year earlier. It now expects full-year revenue to exceed $240 milli
EQUITY | Oct 29, 2026, 01:04 PM UTC
M
Vanda Pharmaceuticals Reports Third-Quarter 2026 Revenue of $69.82M
Revenue rose 24.1% year over year to $69.82 million. Net loss was $22.56 million versus $22.59 million a year earlier; diluted loss per share was $0.37 versus $0.38.
EQUITY | Oct 29, 2026, 12:11 PM UTC
M
Vanda Pharmaceuticals Reports Third-Quarter Revenue of $69.8 Million
EQUITY | Oct 28, 2026, 08:30 PM UTC
M
Vanda Pharmaceuticals Reports $22.6M Third-Quarter Loss
EQUITY | Oct 28, 2026, 08:07 PM UTC
L
Vanda Pharmaceuticals Reports Q3 EPS of USD -0.37
Vanda Pharmaceuticals reported Q3 operating income of USD -23.521 million.
EARNINGS | Oct 28, 2026, 08:02 PM UTC
M
Nereus reduces semaglutide-related vomiting risk in Phase III study
EQUITY | Oct 27, 2026, 10:50 AM UTC
M
Vanda’s Nereus Reduces Semaglutide-Induced Vomiting by 27% in Phase III Trial
EQUITY | Oct 27, 2026, 10:50 AM UTC
M
Vanda Pharmaceuticals to Report Third-Quarter Results October 28
Vanda said it will release third-quarter 2026 results after the market closes on October 28 and host a conference call at 4:30 p.m. ET.
EQUITY | Oct 21, 2026, 09:41 PM UTC
M
Vanda Says Anxiety Drug Failed Late-Stage Study; Puts Program on Hold
Vanda Pharmaceuticals said its experimental social anxiety disorder drug failed the main goal of a late-stage study. The company put the program on hold pending further analysis of the data.
EQUITY | Oct 14, 2026, 09:36 PM UTC
M
Vanda Pharmaceuticals’ VQW-765 Trial Fails to Meet Primary Endpoint
Vanda said the Phase 3 trial of VQW-765 for anxiety did not meet its primary endpoint, which measured distress during the performance phase of the Trier Social Stress Test in women.
EQUITY | Oct 14, 2026, 09:15 PM UTC
L
Vanda Pharmaceuticals updates VQW-765 clinical development program
EQUITY | Oct 14, 2026, 09:00 PM UTC
H
Why Are Nasdaq Futures Rising Premarket? MU, TSLA, CAPR, VNDA, ASTS, HOOD, BA Stocks In Focus
U.S. stock futures were higher early Wednesday as investors brace for the Federal Reserve’s preferred inflation metric, the PCE Price Index, alongside Q2 GDP numbers.As of 4:00 a.m. ET, Nasdaq and S&P 500 futures were up
MACRO | Sep 30, 2026, 08:30 AM UTC
L
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks trailed the S&P 500 and Nasdaq-100 in September, yet Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) bucked the sector’s decline, while Sellas Life Sciences (SLS) awaited key leukemia data and Vanda
NEWS | Sep 30, 2026, 03:48 AM UTC
M
Vanda reports positive Phase III results for HETLIOZ in DSWPD
EARNINGS | Sep 29, 2026, 10:47 PM UTC
L
Vanda Pharmaceuticals Initiated at Outperform by Oppenheimer
Ratings actions from Benzinga: GMT) Vanda Pharmaceuticals Price Target Announced at $10.00/Share by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:22 PM UTC
L
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead
Five approved products anchor a diversified portfolio, with BYSANTI and NEREUS launches driving near-term growth. Key clinical readouts for MDD and GLP-1-induced nausea could unlock major new markets, while commercial in
NEWS | Sep 15, 2026, 02:49 PM UTC
L
VNDA - Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
VNDA - Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
EQUITY | Sep 02, 2026, 08:52 PM UTC
M
Vanda gets EU orphan designation for imsidolimab in pustular psoriasis
Vanda Pharmaceuticals says the European Commission granted orphan designation for imsidolimab for the treatment of generalized pustular psoriasis.
REGULATION | Aug 24, 2026, 11:01 AM UTC
L
Vanda Pharmaceuticals wins European orphan designation for imsidolimab
Vanda Pharmaceuticals (VNDA) says the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis.
REGULATION | Aug 24, 2026, 11:00 AM UTC
L
VNDA - NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
VNDA - NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
EQUITY | Aug 22, 2026, 07:17 PM UTC
L
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est
Vanda Pharmaceuticals (NASDAQ: VNDA ) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.
EARNINGS | Aug 05, 2026, 08:05 PM UTC
L
VNDA VNDA - Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
VNDA VNDA - Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:02 PM UTC
L
VNDA VNDA - Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
VNDA VNDA - Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
EARNINGS | Jul 29, 2026, 08:32 PM UTC
L
VNDA (more) Vanda Pharmaceuticals - announces EMA positive opinion for orphan drug designation of imsidolimab for gpp
VNDA (more) Vanda Pharmaceuticals - announces EMA positive opinion for orphan drug designation of imsidolimab for gpp
EQUITY | Jul 16, 2026, 08:31 PM UTC
L
VNDA Vanda Pharmaceuticals - imsidolimab BLA for gpp under FDA review with target action date December 12, 2026
VNDA Vanda Pharmaceuticals - imsidolimab BLA for gpp under FDA review with target action date December 12, 2026
REGULATION | Jul 16, 2026, 08:30 PM UTC
L
Vanda Pharmaceuticals Gets FDA Rare Pediatric Disease Designation for CMT2S Therapy
() -- Vanda Pharmaceuticals (VNDA) said Tuesday the Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to VCA-894A, its investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth
REGULATION | Jul 07, 2026, 08:55 PM UTC
L
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
The company states: "Vanda Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-T
EQUITY | Jul 07, 2026, 08:46 PM UTC